BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · IEX Real-Time Price · USD
84.09
+0.75 (0.90%)
At close: Jul 19, 2024, 4:00 PM
87.00
+2.91 (3.46%)
Pre-market: Jul 22, 2024, 6:06 AM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for BMRN stock have an average target of 105.95, with a low estimate of 70 and a high estimate of 185. The average target predicts an increase of 26.00% from the current stock price of 84.09.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BMRN stock from 20 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 7 | 7 | 8 | 8 | 7 | 7 |
| Hold | 7 | 7 | 8 | 9 | 9 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 21 | 22 | 21 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $110 → $115 | Buy | Maintains | $110 → $115 | +36.76% | Jun 27, 2024 |
| Baird | Baird | Buy → Hold Downgrades $104 → $72 | Buy → Hold | Downgrades | $104 → $72 | -14.38% | May 17, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $113 | Buy | Initiates | $113 | +34.38% | May 14, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $115 → $112 | Buy | Maintains | $115 → $112 | +33.19% | Apr 26, 2024 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $91 → $89 | Hold | Maintains | $91 → $89 | +5.84% | Apr 26, 2024 |
Financial Forecast
Revenue This Year
2.80B
from 2.42B
Increased by 15.66%
Revenue Next Year
3.16B
from 2.80B
Increased by 12.76%
EPS This Year
1.92
from 0.87
Increased by 120.35%
EPS Next Year
2.93
from 1.92
Increased by 52.94%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.0B | 3.5B | 4.5B | 4.5B | 5.3B |
| Avg | 2.8B | 3.2B | 3.5B | 3.9B | 4.3B |
| Low | 2.6B | 2.8B | 2.9B | 3.3B | 3.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.3% | 24.6% | 41.5% | 27.8% | 36.0% |
| Avg | 15.7% | 12.8% | 12.3% | 10.1% | 10.3% |
| Low | 8.7% | -1.1% | -9.1% | -5.8% | -5.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.02 | 4.24 | 7.56 | 8.36 | 8.88 |
| Avg | 1.92 | 2.93 | 4.12 | 5.96 | 7.00 |
| Low | 1.26 | 1.33 | 1.71 | 4.28 | 4.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 247.6% | 121.1% | 157.8% | 102.9% | 49.0% |
| Avg | 120.4% | 52.9% | 40.5% | 44.8% | 17.3% |
| Low | 45.3% | -30.5% | -41.5% | 4.0% | -22.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.